Ofloxacin in community-acquired lower respiratory infections. A comparison with amoxicillin or erythromycin

J. M. Stocks, R. J. Wallace, D. E. Griffith, J. G. Garcia, R. B. Kohler

Research output: Contribution to journalArticlepeer-review

21 Scopus citations


Ninety-one patients with community-acquired lower respiratory infections were treated orally in a comparative 10-day trial of ofloxacin versus amoxicillin or erythromycin. Approximately one-half of the patients had no major underlying disease and the other half had some form of chronic lung disease. Pneumonia was present in 31 percent of the patients and the remainder had purulent bronchitis. Bacterial pathogens were recovered from 60 percent of the paitents, with Haemophilus influenzae (33 isolates) and Streptococcus pneumoniae (16 isolates) being the most common. Ofloxacin was found to be a safe, well-tolerated therapeutic agent, which was as effective clinically as amoxicillin or erythromycin and with an advantage of less frequent administration. Ofloxacin was more effective than amoxicillin (90 percent versus 75 percent; p = 0.05) in elimination of pathogenic bacteria from lower airway cultures. Caution should be exercised in the use of ofloxacin, at least in short-term treatment regimens, with anaerobic pulmonary infections; additional information is needed for S. pneumoniae given the relatively high minimal inhibitory concentrations for this species.

Original languageEnglish (US)
Pages (from-to)52S-56S
JournalAmerican Journal of Medicine
Issue number6 C
StatePublished - 1989

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Ofloxacin in community-acquired lower respiratory infections. A comparison with amoxicillin or erythromycin'. Together they form a unique fingerprint.

Cite this